All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2020-09-08T08:14:13.000Z

The FDA accepts a supplemental biologics license application for axicabtagene ciloleucel in patients with R/R FL or MZL

Sep 8, 2020
Share:

Bookmark this article

On September 4, 2020, the U.S. Food and Drug Administration (FDA) accepted a supplemental biologics license application (sBLA) for axicabtagene ciloleucel (axi-cel) for the treatment of patients with relapsed or refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL) after two or more prior lines of systemic therapy.1

Axi-cel, an anti-CD19 autologous chimeric antigen receptor (CAR) T-cell product, is already approved for the treatment of adult patients with R/R large B-cell lymphoma (LBCL) after ≥ 2 lines of systemic therapy, and previously the FDA granted breakthrough therapy designation to axi-cel for R/R FL or MZL. In case of approval, axi-cel would be the first commercial CAR T-cell therapy approved for R/R FL or MZL.

The sBLA submission was based on data from the ongoing single-arm, multicenter, open-label, phase II ZUMA-5 trial (NCT03105336). Interim results of this study were reported at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. Axi-cel showed high rates of durable responses and a manageable safety profile (read the full article on the ZUMA-5 study, here).

Axi-cel could represent a valid treatment option for patients with late line R/R FL and MZL who have exhausted other approved treatment options.

  1. Business Wire. Kite submits supplemental biologics license application to U.S. Food and Drug Administration for Yescarta® in relapsed or refractory indolent non-Hodgkin lymphomas. https://www.businesswire.com/news/home/20200904005123/en. Published Sep 04, 2020. Accessed Sep 07, 2020.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
27 votes - 88 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox